Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02323113
Title Safety, Tolerability, and Efficacy of TAK-659 in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (AML)
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Millennium Pharmaceuticals, Inc.
Indications

acute myeloid leukemia

Therapies

Mivavotinib

Age Groups: adult
Covered Countries USA | CAN


No variant requirements are available.